Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 19.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 63,220 shares of the biopharmaceutical company’s stock after selling 14,875 shares during the quarter. Hennion & Walsh Asset Management Inc. owned 0.07% of Ultragenyx Pharmaceutical worth $2,660,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of RARE. Massachusetts Financial Services Co. MA increased its stake in shares of Ultragenyx Pharmaceutical by 38.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 370,247 shares of the biopharmaceutical company’s stock worth $15,217,000 after buying an additional 103,280 shares during the last quarter. Amalgamated Bank increased its holdings in Ultragenyx Pharmaceutical by 13.4% in the second quarter. Amalgamated Bank now owns 5,896 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 696 shares during the last quarter. Sei Investments Co. raised its stake in Ultragenyx Pharmaceutical by 39.1% during the second quarter. Sei Investments Co. now owns 91,799 shares of the biopharmaceutical company’s stock valued at $3,773,000 after buying an additional 25,803 shares in the last quarter. ProShare Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical by 83.4% during the 2nd quarter. ProShare Advisors LLC now owns 11,142 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 5,068 shares during the last quarter. Finally, Xponance Inc. grew its position in shares of Ultragenyx Pharmaceutical by 13.0% in the 2nd quarter. Xponance Inc. now owns 11,091 shares of the biopharmaceutical company’s stock worth $456,000 after acquiring an additional 1,279 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 11,727 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the sale, the chief executive officer now owns 2,183,985 shares of the company’s stock, valued at $92,229,686.55. The trade was a 0.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on RARE shares. Cantor Fitzgerald restated an “overweight” rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. JPMorgan Chase & Co. reduced their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Piper Sandler raised their target price on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $92.29.

Ultragenyx Pharmaceutical Trading Down 0.3 %

Shares of RARE stock opened at $40.85 on Friday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $37.02 and a 1 year high of $60.37. The stock has a fifty day moving average of $45.30 and a two-hundred day moving average of $49.52.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The company’s revenue was up 42.3% on a year-over-year basis. During the same period in the previous year, the business earned ($2.23) earnings per share. As a group, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.21 earnings per share for the current year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.